NiKang Therapeutics welcomes Dr. Anne Borgman to its Board of Directors

– USA, DE –  NiKang Therapeutics Inc., a clinical-stage biotech company, today announced the appointment of Dr. Anne Borgman to its Board of Directors, bringing over 20 years of experience in the clinical development of oncology and hematology therapeutics.

“We are thrilled to welcome Dr. Borgman to our Board of Directors at this critical stage of NiKang. As a highly accomplished executive, Dr. Borgman brings in much needed expertise in developing targeted oncology drugs to NiKang. We look forward to her advice and engagement in guiding us developing multiple drugs to help patients fight against cancer,” said Co-founder and CEO, Dr. Zhenhai Gao.

About Dr. Anne Borgman

Dr. Borgman has led teams to the successful approval of several oncology drugs including recombinant asparaginase using the intensive Real-Time Oncology Review process while she was VP and Global Therapeutic Area Lead, Hematology-Oncology at Jazz Pharmaceuticals, and cabozantinib for the treatment of renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer while she served as VP of Clinical Research and Development at Exelixis. As CMO at Hana Biosciences, Dr. Borgman led the filing for accelerated approval for liposomal vincristine in adult relapsed acute lymphoblastic lymphoma. Dr. Borgman currently serves on the Board of Directors at Curis, Inc. and NextCure, Inc. She has previously held the position of Consulting Associate Professor at Stanford University in the Department of Pediatrics in the School of Medicine. Before Stanford, Dr. Borgman held positions of Consulting Attending Physician at the University of Chicago Comer Children’s Hospital in the Department of Pediatric Hematology/Oncology and Stem Cell Transplant and Global Project Head early in her career at Abbott Laboratories.

“I am excited to join NiKang’s Board,” said Dr. Anne Borgman. “I look forward to working with the management team alongside my fellow Board members to advance NiKang’s innovative medicines to help more patients in need.”

Dr. Borgman earned her M.D. from Loyola University of Chicago’s Stritch School of Medicine, completed a residency in pediatrics at Texas Children’s Hospital, Baylor College of Medicine, and a fellowship in pediatric hematology-oncology and stem cell transplant at UCLA David Geffen School of Medicine.

About NiKang Therapeutics

NiKang Therapeutics is a clinical-stage biotech company focused on discovering and developing innovative small-molecule oncology medicines to help patients with unmet medical needs. Our target selection is driven by deep insights into disease biology and molecular pathways. Our discovery approach is informed by target structure biology and capitalizes on structure-based drug design. The successful implementation of our strategy enables us to rapidly and efficiently discover and advance proprietary drugs.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.